These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32507911)

  • 1. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
    Bekoz H; Ozbalak M; Karadurmus N; Paydas S; Turker A; Toptas T; Tuglular TF; Altuntas F; Cakar MK; Sonmez M; Gulbas Z; Demir N; Kaynar L; Yildirim R; Karadogan I; Arat M; Kapucu I; Aslan NA; Ozkocaman V; Turgut M; Yuksel MK; Ozcan M; Hacioglu SK; Barista I; Demirkaya M; Saydam G; Toprak SK; Yilmaz M; Demirkol O; Ferhanoglu B
    Ann Hematol; 2020 Nov; 99(11):2565-2576. PubMed ID: 32507911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
    Beköz H; Karadurmuş N; Paydaş S; Türker A; Toptaş T; Fıratlı Tuğlular T; Sönmez M; Gülbaş Z; Tekgündüz E; Kaya AH; Özbalak M; Taştemir N; Kaynar L; Yıldırım R; Karadoğan I; Arat M; Pepedil Tanrıkulu F; Özkocaman V; Abalı H; Turgut M; Kurt Yüksel M; Özcan M; Doğu MH; Kabukçu Hacıoğlu S; Barışta I; Demirkaya M; Köseoğlu FD; Toprak SK; Yılmaz M; Demirkürek HC; Demirkol O; Ferhanoğlu B
    Ann Oncol; 2017 Oct; 28(10):2496-2502. PubMed ID: 28961828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
    Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
    Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.
    Özbalak M; Salihoğlu A; Soysal T; Karadoğan İ; Paydaş S; Özdemir E; Yıldız B; Karadurmuş N; Kaynar L; Yagci M; Özkocaman V; Topçuoğlu P; Özcan M; Birtaş E; Göker H; Ferhanoglu B
    Ann Hematol; 2020 Feb; 99(2):301-307. PubMed ID: 31844933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
    Chan TSY; Hwang YY; Khong PL; Leung AYH; Chim CS; Tse EWC; Kwong YL
    Hematol Oncol; 2020 Dec; 38(5):726-736. PubMed ID: 32786092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.
    Manson G; Mear JB; Herbaux C; Schiano JM; Casasnovas O; Stamatoullas A; Deau B; Schmitt A; Garnier G; Regny C; Bouabdallah K; Moles-Moreau MP; Ghesquieres H; Tempescul A; Dulery R; Nicolas-Virelizier E; Delmer A; Borel C; Chauchet A; Damotte D; Dercle L; Brice P; Houot R;
    Eur J Cancer; 2019 Jul; 115():47-56. PubMed ID: 31082693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
    Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
    J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients.
    Halahleh K; Al Sawajneh S; Saleh Y; Shahin O; Abufara A; Ma'koseh M; Abdel-Razeq R; Barakat F; Abdelkhaleq H; Al-Hassan N; Atiyyat R; Al-Faker N; Omari Z; Ghatasheh H; Jaradat I; Muradi I; Iyad S; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):589-595. PubMed ID: 35490153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
    Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
    Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.
    Herbaux C; Gauthier J; Brice P; Drumez E; Ysebaert L; Doyen H; Fornecker L; Bouabdallah K; Manson G; Ghesquières H; Tabrizi R; Hermet E; Lazarovici J; Thiebaut-Bertrand A; Chauchet A; Demarquette H; Boyle E; Houot R; Yakoub-Agha I; Morschhauser F
    Blood; 2017 May; 129(18):2471-2478. PubMed ID: 28270452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real world effectiveness and safety of nivolumab in patients with relapsed or refractory classical hodgkin lymphoma.
    Lorente Fernández L; Romero Domínguez S; Albert Marí A; Núñez Benito E; López Briz E; Poveda Andrés JL
    Farm Hosp; 2024 Jun; ():. PubMed ID: 38839541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma.
    Fedorova LV; Lepik KV; Mikhailova NB; Kondakova EV; Zalyalov YR; Baykov VV; Babenko EV; Kozlov AV; Moiseev IS; Afanasyev BV
    Ann Hematol; 2021 Mar; 100(3):691-698. PubMed ID: 33528609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
    Fernández LL; Domínguez SR; Marí AA; Benito EN; Briz EL; Andrés JLP
    Farm Hosp; 2024 Oct; ():. PubMed ID: 39424522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.
    De Filippi R; Morabito F; Santoro A; Tripepi G; D'Alò F; Rigacci L; Ricci F; Morelli E; Zinzani PL; Pinto A
    J Transl Med; 2021 Dec; 19(1):489. PubMed ID: 34852840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain.
    Martínez C; Carpio C; Heras I; Ríos-Herranz E; Buch J; Gutierrez A; Romero S; Zeberio I; García-García I; Rodriguez-Izquierdo A; Alonso R; Bargay J; Barrenetxea C; Domingo-Doménech E; de Haro ME; Palomera L; García-Sanz R;
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1534-1542. PubMed ID: 32068094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
    Haverkos BM; Abbott D; Hamadani M; Armand P; Flowers ME; Merryman R; Kamdar M; Kanate AS; Saad A; Mehta A; Ganguly S; Fenske TS; Hari P; Lowsky R; Andritsos L; Jagasia M; Bashey A; Brown S; Bachanova V; Stephens D; Mineishi S; Nakamura R; Chen YB; Blazar BR; Gutman J; Devine SM
    Blood; 2017 Jul; 130(2):221-228. PubMed ID: 28468799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
    Vardhana S; Cicero K; Velez MJ; Moskowitz CH
    Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.